Cocrystal Pharma, Inc.
COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.82
Price-5.50%
-$0.05
1Y
Price
Market Cap
$11.306m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$225k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$8.829m
+44.8%
1y CAGR+33.7%
3y CAGR-18.2%
5y CAGREPS
-$0.74
+45.4%
1y CAGR+48.5%
3y CAGR-3.1%
5y CAGRBook Value
$4.116m
$7.426m
Assets$3.310m
Liabilities$1.424m
DebtDebt to Assets
19.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$7.792m
+40.5%
1y CAGR+20.1%
3y CAGR-2.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company